NASDAQ:RADX - ADR
Taking everything into account, RADX scores 3 out of 10 in our fundamental rating. RADX was compared to 545 industry peers in the Biotechnology industry. While RADX seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, RADX is valued expensive at the moment.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -45.34% | ||
ROE | -78.79% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Altman-Z | -1.68 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 3.37 | ||
Quick Ratio | 3.37 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
NASDAQ:RADX (8/29/2025, 8:00:01 PM)
5.49
-0.21 (-3.68%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 38.89 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 1.23 | ||
P/tB | 12.59 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -45.34% | ||
ROE | -78.79% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | N/A | ||
Cap/Sales | N/A | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 3.37 | ||
Quick Ratio | 3.37 | ||
Altman-Z | -1.68 |